The Cornell Daily Sun (https://cornellsun.com/author/srishtityagi/page/3/)
As COVID-19 continues to claim over one-thousand American lives a day, Black people have been up to twice as likely as the general population to die from the disease. The reasons for the striking racial disparity are complex, but often stem from social inequities that can create an elevated risk for contracting or dying from coronavirus, researchers say.
After stumbling upon a box of N95 respirators in her New York City apartment and delivering them to Mount Sinai West’s Emergency Department, Anna Azvolinsky and her husband Joel Weingarten wondered what else they could do to help during a crisis.
As people continue to huddle indoors, avoiding their usual daily commute to work and school, it is inevitable that humans’ dramatic new relationship with the world would have a major impact on the state of the environment.
In the race to develop a safe, effective treatment for COVID-19, biotech companies like Regeneron and Vir Biotechnology, led by Cornell alumni, have turned to antibodies — which are naturally created by the human immune system — as a form of therapeutic treatment.
But what are antibodies, and how can they be repurposed into drugs to help people recover from COVID-19?
In a time of uncertainty and fear surrounding the pandemic, rumors and misinformation continue to spread through social media and word of mouth — oftentimes drowning out expert voices and confusing those seeking information to further understand the unprecedented situation.
What are clinical trials, and how do they work?
Weill Cornell physician-scientist Dr. Marshall Glesby, who works for the Clinical and Translational Science Center, explained that clinical trials are research studies that test how well new medical interventions or approaches work in people.
For over 50 years, Cornell has made astronomical contributions in the ongoing efforts to explore and understand the mysterious inner workings of Earth’s rust-colored neighbor, Mars. In honor of these decades of research and discovery, The Sun illuminates the achievements of Cornellians past, present and future in their tireless expedition towards revealing the secrets of the Red Planet.
Students take a stand against Cornell’s investment in fossil fuels with a demonstration on the Ag Quad, pointing to the industry’s toll on indigenous women.
Whether you decide to actually meet your Perfect Match, go out with your significant other or stay in for a night of Netflix with friends, Valentine’s Day can be an opportunity to appreciate the bonds and love we have for each other as humans. But the bonds we’ve formed over the course of our lives don’t just start with us — human bonding is as old as humanity itself.
Researchers, healthcare providers and global health officials who worked hard to grapple with the devastating Ebola outbreak of West Africa between 2014 and 2016 can finally breathe a sigh of relief — the very first Ebola vaccine was finally approved in Europe. Known as Ervebo, this Ebola vaccine is manufactured by the biopharmaceutical company Merck and was granted marketing authorization by the European Commission on November 11. Prof. Gary Whittaker, virology, shared his insight on the inner workings of the vaccine and its development, as well as what this landmark achievement means for the future of global health. Whittaker explained that the vaccine itself is actually a recombinant virus, based on the backbone of vesicular stomatitis virus originating from sheep and goats. “[VSV] is very efficiently growing and relatively easy to make, [so] it’s engineered to express the glycoprotein of Ebola … it generates the immune response against the Ebola virus glycoprotein, which is equivalent to the surface protein of Ebola,” Whittaker said.